Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
December 06 2016 - 4:05PM
Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today
announced that its Board of Directors has declared a quarterly cash
dividend payment on the Company's 10.50% Series E Convertible
Preferred Stock (the "Series E Preferred Stock").
The quarterly dividend on the Series E Preferred
Stock is payable on January 3, 2017 to holders of record at the
close of business on December 16, 2016.
The quarterly dividend payment on the Series E
Preferred Stock will be $0.65625 per share, which is equivalent to
an annualized 10.50% per share, based on the $25.00 per share
stated liquidation preference, accruing from October 1, 2016
through December 31, 2016. The Series E Preferred Stock is listed
on the NASDAQ Capital Market and trades under the ticker symbol
"PPHMP".
About Peregrine Pharmaceuticals,
Inc.Peregrine Pharmaceuticals, Inc. is a biopharmaceutical
company committed to improving the lives of patients by delivering
high quality pharmaceutical products through its contract
development and manufacturing organization (CDMO) services and
through advancing and licensing its investigational immunotherapy
and related products. Peregrine's in-house CDMO services,
including cGMP manufacturing and development capabilities, are
provided through its wholly-owned subsidiary Avid Bioservices, Inc.
(www.avidbio.com), which provides development and biomanufacturing
services for both Peregrine and third-party customers. The company
is also working to evaluate its lead immunotherapy candidate,
bavituximab, in combination with immune stimulating therapies for
the treatment of various cancers, and developing its proprietary
exosome technology for the detection and monitoring of
cancer. For more information, please visit
www.peregrineinc.com.
Contacts:
Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024